Skip to main content

2011 | OriginalPaper | Buchkapitel

2. Pharmakodynamik

verfasst von : Prof. Dr. Bernd Antkowiak, Prof. Dr. Dr. Ingolf Cascorbi

Erschienen in: Pharmakotherapie in der Anästhesie und Intensivmedizin

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Zur Gruppe der Anästhetika gehören Substanzen mit sehr unterschiedlichen chemischen Strukturformeln (◘Abb. 2.1). Hierzu zählen Hydrocarbone (Chloroform, Halothan), Derivate des Ether (Isofluran, Desfluran, Sevofluran), Phenole (Propofol), Imidazolderivate (Etomidat, Dexmedetomidin), Phencyclidine (Ketamin), Steroide (Alphaxalone), Barbiturate (Thiopental), Benzodiazepine (Midazolam) und Edelgase (Xenon).
Literatur
[1]
Zurück zum Zitat Antkowiak, B (2001) How do gerneral anaesthetis work? Neuro-wissenschaften 88:201–213CrossRef Antkowiak, B (2001) How do gerneral anaesthetis work? Neuro-wissenschaften 88:201–213CrossRef
[2]
Zurück zum Zitat Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–473PubMedCrossRef Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–473PubMedCrossRef
[3]
Zurück zum Zitat Daly AK (2009) Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med 1:10PubMedCrossRef Daly AK (2009) Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med 1:10PubMedCrossRef
[4]
Zurück zum Zitat Drago A, De Ronchi D, Serretti A (2009) Pharmacogenetics of antidepressant response: an update. Hum Genomics 3:257–274PubMedCrossRef Drago A, De Ronchi D, Serretti A (2009) Pharmacogenetics of antidepressant response: an update. Hum Genomics 3:257–274PubMedCrossRef
[5]
Zurück zum Zitat Drexler B, Grasshoff C, Rudolph U, Unertl K, Antkowiak B (2006) The GABA(A) receptor family : Possibilities for the development of better anesthetics. Anaesthesist 55:287–295PubMedCrossRef Drexler B, Grasshoff C, Rudolph U, Unertl K, Antkowiak B (2006) The GABA(A) receptor family : Possibilities for the development of better anesthetics. Anaesthesist 55:287–295PubMedCrossRef
[6]
Zurück zum Zitat Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57: 119–137PubMedCrossRef Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57: 119–137PubMedCrossRef
[7]
Zurück zum Zitat Franks NP (2006) Molecular targets underlying general anaesthesia. Brit J Pharmacol 147: S72–S81CrossRef Franks NP (2006) Molecular targets underlying general anaesthesia. Brit J Pharmacol 147: S72–S81CrossRef
[8]
Zurück zum Zitat Grasshoff C, Rudolph U, Antkowiak B (2005) Molecular and systemic mechanisms of general anaesthesia: the,multi-site and multiple mechanisms' concept. Curr Opin Anaesth 18:386–391CrossRef Grasshoff C, Rudolph U, Antkowiak B (2005) Molecular and systemic mechanisms of general anaesthesia: the,multi-site and multiple mechanisms' concept. Curr Opin Anaesth 18:386–391CrossRef
[9]
Zurück zum Zitat Hemmings HC, Akabas MH, Goldstein PA et al. (2005) Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci 26:503–510PubMedCrossRef Hemmings HC, Akabas MH, Goldstein PA et al. (2005) Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci 26:503–510PubMedCrossRef
[10]
Zurück zum Zitat Hughes AR, Spreen WR, Mosteller M et al. (2008) Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 8:365–374PubMedCrossRef Hughes AR, Spreen WR, Mosteller M et al. (2008) Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 8:365–374PubMedCrossRef
[11]
Zurück zum Zitat Kaiser R, Sezer O, Papies A et al. (2002) Patient-tailored anti-emetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811PubMedCrossRef Kaiser R, Sezer O, Papies A et al. (2002) Patient-tailored anti-emetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811PubMedCrossRef
[12]
Zurück zum Zitat Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297–302PubMed Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297–302PubMed
[13]
Zurück zum Zitat La Du BN, Bartels CF, Nogueira CP, Arpagaus M, Lockridge O (1991) Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol 11:79–89PubMedCrossRef La Du BN, Bartels CF, Nogueira CP, Arpagaus M, Lockridge O (1991) Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol 11:79–89PubMedCrossRef
[14]
Zurück zum Zitat Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293PubMedCrossRef Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293PubMedCrossRef
[15]
Zurück zum Zitat Link E, Parish S, Armitage J et al. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N EngI J Med 359:789–799CrossRef Link E, Parish S, Armitage J et al. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N EngI J Med 359:789–799CrossRef
[16]
Zurück zum Zitat Loscher W, Delanty N (2009) MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharma-cogenomics 10:711–713CrossRef Loscher W, Delanty N (2009) MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharma-cogenomics 10:711–713CrossRef
[17]
Zurück zum Zitat Lotsch J, Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82–89PubMedCrossRef Lotsch J, Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82–89PubMedCrossRef
[18]
Zurück zum Zitat Lotsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1–5PubMedCrossRef Lotsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1–5PubMedCrossRef
[19]
Zurück zum Zitat Mariani G, Fasolo A, De Benedictis E, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6: 93–104PubMedCrossRef Mariani G, Fasolo A, De Benedictis E, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6: 93–104PubMedCrossRef
[20]
Zurück zum Zitat Nagele P, Zeugswetter B, Wiener C et al. (2008) Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 109:36–43PubMedCrossRef Nagele P, Zeugswetter B, Wiener C et al. (2008) Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 109:36–43PubMedCrossRef
[21]
Zurück zum Zitat Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802PubMedCrossRef Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802PubMedCrossRef
[22]
Zurück zum Zitat Rau T, Wuttke H, Michels LM et al. (2009) Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85:269–272PubMedCrossRef Rau T, Wuttke H, Michels LM et al. (2009) Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85:269–272PubMedCrossRef
[23]
Zurück zum Zitat Robinson RL, Anetseder MJ, Brancadoro V et al. (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 11:342–348PubMedCrossRef Robinson RL, Anetseder MJ, Brancadoro V et al. (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 11:342–348PubMedCrossRef
[24]
Zurück zum Zitat Rudolph U, Antkowiak B (2004) Molecular and neuronal substrates for general anaesthetics. Nature Rev Neuroscience 5: 709–720CrossRef Rudolph U, Antkowiak B (2004) Molecular and neuronal substrates for general anaesthetics. Nature Rev Neuroscience 5: 709–720CrossRef
[25]
Zurück zum Zitat Simon T, Verstuyft C, Mary-Krause M et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N EngI J Med 360:363–375CrossRef Simon T, Verstuyft C, Mary-Krause M et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N EngI J Med 360:363–375CrossRef
[26]
Zurück zum Zitat Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of betal- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135–1142PubMedCrossRef Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of betal- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135–1142PubMedCrossRef
[27]
Zurück zum Zitat Sonner JM, Antognini JF, Dutton RC et al. (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Anal 97:718–740CrossRef Sonner JM, Antognini JF, Dutton RC et al. (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Anal 97:718–740CrossRef
[28]
Zurück zum Zitat Steimer W, Zopf K, von Amelunxen S et al. (2005) Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51:376–385PubMedCrossRef Steimer W, Zopf K, von Amelunxen S et al. (2005) Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51:376–385PubMedCrossRef
[29]
Zurück zum Zitat Urban BW (2002) Current assessment of targets and theories of anaesthesia. Br J Anaesth 89:165–183 Urban BW (2002) Current assessment of targets and theories of anaesthesia. Br J Anaesth 89:165–183
[30]
Zurück zum Zitat Urban BW, Bleckwenn M (2002) Concepts and correlations relevant to general anaesthesia. Br J Anaesth 89:3–16PubMedCrossRef Urban BW, Bleckwenn M (2002) Concepts and correlations relevant to general anaesthesia. Br J Anaesth 89:3–16PubMedCrossRef
[31]
Zurück zum Zitat Urban BW, Bleckwenn M, Barann M (2006) Interactions of anesthetics with their targets: Non-specific, specific or both? Pharmacology therapeutics 111: 729–770PubMedCrossRef Urban BW, Bleckwenn M, Barann M (2006) Interactions of anesthetics with their targets: Non-specific, specific or both? Pharmacology therapeutics 111: 729–770PubMedCrossRef
[32]
Zurück zum Zitat Yin T, Maekawa K, Kamide K et al. (2008) Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549–1557PubMedCrossRef Yin T, Maekawa K, Kamide K et al. (2008) Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549–1557PubMedCrossRef
Metadaten
Titel
Pharmakodynamik
verfasst von
Prof. Dr. Bernd Antkowiak
Prof. Dr. Dr. Ingolf Cascorbi
Copyright-Jahr
2011
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-540-79156-0_2

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.